481 related articles for article (PubMed ID: 14535624)
1. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
[TBL] [Abstract][Full Text] [Related]
3. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine.
Zhao Q; Tang XC
Eur J Pharmacol; 2002 Nov; 455(2-3):101-7. PubMed ID: 12445575
[TBL] [Abstract][Full Text] [Related]
4. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
[TBL] [Abstract][Full Text] [Related]
5. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
7. Effects of bis(7)-tacrine, a novel anti-Alzheimer's agent, on rat brain AChE.
Wang H; Carlier PR; Ho WL; Wu DC; Lee NT; Li CP; Pang YP; Han YF
Neuroreport; 1999 Mar; 10(4):789-93. PubMed ID: 10208549
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981
[TBL] [Abstract][Full Text] [Related]
9. Comparison of donepezil-, tacrine-, rivastigmine- and metrifonate-induced central and peripheral cholinergically mediated responses in the rat.
Dronfield S; Egan K; Marsden CA; Green AR
J Psychopharmacol; 2000; 14(3):275-9. PubMed ID: 11106308
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
12. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats.
Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
Eur J Pharmacol; 1999 Sep; 380(2-3):101-7. PubMed ID: 10513568
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Amici S; Lanari A; Romani R; Antognelli C; Gallai V; Parnetti L
Mech Ageing Dev; 2001 Nov; 122(16):2057-62. PubMed ID: 11589922
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
[TBL] [Abstract][Full Text] [Related]
15. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
17. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
18. N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine.
Cerbai F; Giovannini MG; Melani C; Enz A; Pepeu G
Eur J Pharmacol; 2007 Oct; 572(2-3):142-50. PubMed ID: 17643410
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
20. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats.
Kosasa T; Kuriya Y; Yamanishi Y
Jpn J Pharmacol; 1999 Oct; 81(2):216-22. PubMed ID: 10591480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
